UNITED GREENERIES
DEAD

Serial Number

86532961

Owner

UNITED GREENERIES HOLDINGS LTD.

Attorney

Kimberly N. Fisher

Filing Date

Feb 12, 2015

Add to watchlist:

No watchlists yet
View on USPTO

UNITED GREENERIES Trademark

Serial Number: 86532961

UNITED GREENERIES is a trademark filed by UNITED GREENERIES HOLDINGS LTD. on February 12, 2015. The trademark is classified under Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

UNITED GREENERIES HOLDINGS LTD. (5 trademarks)

704-595 HOWE STREET
VANCOUVER V6C2T5 , CA

Entity Type: 13

MMJ Bioscience Inc. (6 trademarks)

704 - 595 Howe Street
Vancouver V6C2T5 , CA

Entity Type: 03

Trademark Details

Filing Date

February 12, 2015

Registration Date

Not Registered

Goods & Services

Magnetically encoded cards for medical purposes, namely, membership and identification cards; magnetically encoded cards for use in connection with customer loyalty, rewards, bonus points, and discount programs

Cannabis compounds for medicinal purposes and cannabis based pharmaceuticals and nutraceuticals comprised of legal cannabis products for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; medicated cannabis preparations in the form of personal care preparations for the body, namely, creams, oils, emollients, ointments, rubs, lotions, and salves comprising legal cannabis products; synthetic narcotics for medical use; pharmaceutical preparations for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; pharmaceutical preparations containing one or more legal cannabinoids as the active ingredient for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; medicines containing a legal tetrahydrocannabinol extract for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; medicines derived from legal cannabis for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; nutraceuticals and medicines comprising legal cannabis products derived from and related to the cannabis plant for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; medicated products, plants, dried plant material, seeds and medicines derived from and related to the cannabis plant, namely, anti-inflammatories, analgesics, sedatives, appetite stimulants, anti-nauseants, intraocular pressure reducers, anti-tumors antioxidants, antidepressants and antihypertensives comprised of legal cannabis products

Cannabis compounds not for medicinal purposes comprised of legal cannabis products; unmedicated cannabis preparations and derivative products in the form of personal care preparations for the body, namely, creams, oils, emollients, ointments, rubs, lotions, and salves, comprised of legal cannabis products; unmedicated products, plants, dried plant material, seeds and medicines derived from and related to the cannabis plant, namely, anti-inflammatories, analgesics, sedatives, appetite stimulants, anti-nauseants, intraocular pressure reducers, anti-tumors antioxidants, antidepressants and antihypertensives comprised of legal cannabis products

Medical dispensary featuring cannabis compounds for medicinal purposes and cannabis based pharmaceuticals and nutraceuticals comprised of legal cannabis products; online operation of a medical dispensary featuring cannabis compounds for medicinal purposes and cannabis based pharmaceuticals and nutraceuticals comprised of legal cannabis products; operation of a retail store featuring cannabis compounds for medicinal purposes and cannabis based pharmaceuticals and nutraceuticals comprised of legal cannabis products; retail and wholesale store reward programs, namely, arranging and conducting incentive reward programs to promote the sale of cannabis compounds for medicinal purposes and cannabis based pharmaceuticals and nutraceuticals comprised of legal cannabis products; promoting the goods and services of others by means of the issuance of loyalty rewards cards, namely, providing identification cards for use in connection with customer loyalty, rewards, bonus points, and discount programs

Operation of a web site that provides online social networking

Operation of a computer database featuring medical information in the field of medical marihuana; operation of a website containing medical information in the field of marihuana and cannabis

Medical research services; medical research services in the field of cannabis and medical marihuana; product development services

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jan 7, 2021 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jan 7, 2021 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
Jun 26, 2020 GNFN
FINAL REFUSAL E-MAILED
Jun 26, 2020 GNFR
FINAL REFUSAL WRITTEN
Jun 26, 2020 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 11, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 10, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 10, 2020 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 28, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 28, 2020 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 11, 2019 GNRN
NON-FINAL ACTION E-MAILED
Dec 11, 2019 GNRT
NON-FINAL ACTION WRITTEN
Dec 11, 2019 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 30, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 30, 2019 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Sep 27, 2019 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Mar 27, 2019 GNS2
INQUIRY TO SUSPENSION E-MAILED
Mar 27, 2019 GNSI
SUSPENSION INQUIRY WRITTEN
Mar 27, 2019 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Mar 25, 2019 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sep 24, 2018 GNS3
LETTER OF SUSPENSION E-MAILED
Sep 24, 2018 GNSL
SUSPENSION LETTER WRITTEN
Sep 24, 2018 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 24, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 24, 2018 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Sep 17, 2018 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Mar 21, 2018 GNS2
INQUIRY TO SUSPENSION E-MAILED
Mar 21, 2018 GNSI
SUSPENSION INQUIRY WRITTEN
Mar 21, 2018 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Mar 19, 2018 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sep 12, 2017 GNS3
LETTER OF SUSPENSION E-MAILED
Sep 12, 2017 GNSL
SUSPENSION LETTER WRITTEN
Sep 12, 2017 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 5, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 5, 2017 CRFA
ASSIGNED TO LIE
Aug 31, 2017 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Aug 17, 2017 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Feb 20, 2017 GNS2
INQUIRY TO SUSPENSION E-MAILED
Feb 20, 2017 GNSI
SUSPENSION INQUIRY WRITTEN
Feb 20, 2017 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Feb 17, 2017 RCCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Feb 8, 2017 ASGN
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 12, 2017 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 12, 2017 REAP
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 1, 2016 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 1, 2016 GNSL
SUSPENSION LETTER WRITTEN
Aug 1, 2016 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 6, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 6, 2016 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jun 28, 2016 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jun 28, 2016 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jun 28, 2016 GNSI
SUSPENSION INQUIRY WRITTEN
Jun 28, 2016 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jun 24, 2016 RCCK
ASSIGNED TO LIE
Jun 23, 2016 ALIE
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 14, 2015 GNS3
LETTER OF SUSPENSION E-MAILED
Dec 14, 2015 GNSL
SUSPENSION LETTER WRITTEN
Dec 14, 2015 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 20, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 19, 2015 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 19, 2015 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 19, 2015 TCCA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 19, 2015 GNRN
NON-FINAL ACTION E-MAILED
May 19, 2015 GNRT
NON-FINAL ACTION WRITTEN
May 19, 2015 CNRT
ASSIGNED TO EXAMINER
May 5, 2015 DOCK
ASSIGNED TO EXAMINER
Apr 15, 2015 DOCK
ASSIGNED TO EXAMINER
Apr 14, 2015 DOCK
ASSIGNED TO EXAMINER
Apr 13, 2015 DOCK
ASSIGNED TO EXAMINER
Apr 13, 2015 DOCK
ASSIGNED TO EXAMINER
Mar 6, 2015 DOCK
ASSIGNED TO EXAMINER
Mar 4, 2015 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 27, 2015 NWOS